Journal: Antimicrobial Agents and Chemotherapy
Article Title: Improvement of the Pharmacokinetics and In Vivo Antibacterial Efficacy of a Novel Type IIa Topoisomerase Inhibitor by Formulation in Liposomes
doi: 10.1128/AAC.00163-13
Figure Lengend Snippet: Comparison of MICs between free compound 1 and compound 1-containing liposomes made of various lipids a
Article Snippet: Strain Free MIC (μM) ( n = 10) Liposomal MIC/Free MIC DSPC:chol (1:1) ( n = 1) at 0.31 mol compound 1/mol lipid DPPC:chol (1:1) ( n = 2) at 0.24, 0.32 mol compound 1/mol lipid DMPC:chol (1:1) ( n = 1) at 0.31 mol compound 1/mol lipid DAPC:chol (1:1) ( n = 1) at 0.54 mol compound 1/mol lipid SM:chol (11:9) ( n = 1) at 0.19 mol compound 1/mol lipid Egg PC:chol:DOTAP (3:4:3) ( n = 1) at 0.10 mol compound 1/mol lipid Egg PC:DOPE:DOTAP (3:4:3) ( n = 1) at 0.18 mol compound 1/mol lipid PEG-DSPE:HSPC chol (1:10:9) b ( n = 1) at 0.24 mol compound 1/mol lipid Egg PC:PEG-DSPE (19:1) ( n = 1) at 0.08 mol compound 1/mol lipid H. influenzae ATCC 51907 3.1–6.2 1 1, 2 2 1 1 1 1 0.5 1 H. influenzae AcrB − 0.1–0.7 1 1, 4 2 1 1 1 8 2 1 M. catarrhalis ATCC 43617 0.03–0.2 1 0.5, 1 1 0.5 0.5 1 1 1 1 E. coli K-12 0.7–1.5 1 1 1 1 1 1 1 1 1 E. coli TolC − 0.01–0.1 0.5 0.5, 1 1 0.5 1 1 0.5 0.5 1 E. faecium 073 0.8–1.6 1 1 1 1 1 0.5 1 1 0.5 S. aureus MSQS 0.04–0.2 1 0.5, 1 1 1 2 2 0.5 1 1 S. aureus MRQR 0.1–0.4 1 1 1 1 1 1 1 0.5 0.5 P. aeruginosa PAO1 11–12 1 1 1 1 1 1 1 1 1 P. aeruginosa MexABCDXY − 0.1–0.4 1 1, 2 1 1 1 1 1 1 1 K. pneumoniae 1865 6.2–25 2 1, 2 0.5 1 1 0.5 1 0.5 0.5 E. cloacae 2011 12–48 1 1 1 1 1 1 1 1 1 S. pyogenes 838 0.4–0.7 1 1 1 1 1 1 1 2 1 S. pneumoniae 548 NC007466 0.4 1 1 1 1 1 1 1 1 1 S. pneumoniae 358 (Pen r Ery r ) 0.4–0.8 1 1 1 1 1 0.5 1 1 1 Open in a separate window a Each compound 1 liposome preparation was paired with free compound 1 in the same assay plate.
Techniques: Comparison, Liposomes
ATCC is a verified supplier 
ATCC manufactures this product 
